Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

Autor: Roland Van Velthoven, Cees van de Beek, Pierre Scalliet, Marc Colombel, Geertjan van Tienhoven, Bertrand Tombal, Hein Van Poppel, Karin Haustermans, Paul C.M.S. Verhagen, Antony Verbaeys, Thomas C. Gasser, Alphonsus C.M. van den Bergh, Cora N. Sternberg, Laurence Collette, Jean-François Bosset, Michel Bolla, Theo M. de Reijke, Luigi F. Da Pozzo, K. Vekemans
Přispěvatelé: Erasmus MC other, Urology, CCA -Cancer Center Amsterdam, Radiotherapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Bolla, M, van Poppel, H, Tombal, B, Vekemans, K, Da Pozzo, L, de Reijke, T, Verbaeys, A, Bosset, J, van Velthoven, R, Colombel, M, van de Beek, C, Verhagen, P, RS: MHeNs School for Mental Health and Neuroscience, Urologie
Rok vydání: 2012
Předmět:
Zdroj: Lancet (UK), 380(9858), 2018-2027. Elsevier Ltd.
Lancet, 380(9858), 2018-2027. Elsevier Limited
LANCET, 380(9858), 2018-2027. ELSEVIER SCIENCE INC
Lancet, 380(9858), 2018-2027. Elsevier Science
ISSN: 1474-547X
0140-6736
Popis: We report the long-term results of a trial of immediate postoperative irradiation versus a wait-and-see policy in patients with prostate cancer extending beyond the prostate, to confirm whether previously reported progression-free survival was sustained.This randomised, phase 3, controlled trial recruited patients aged 75 years or younger with untreated cT0-3 prostate cancer (WHO performance status 0 or 1) from 37 institutions across Europe. Eligible patients were randomly assigned centrally (1:1) to postoperative irradiation (60 Gy of conventional irradiation to the surgical bed for 6 weeks) or to a wait-and-see policy until biochemical progression (increase in prostate-specific antigen0·2 μg/L confirmed twice at least 2 weeks apart). We analysed the primary endpoint, biochemical progression-free survival, by intention to treat (two-sided test for difference at α=0.05, adjusted for one interim analysis) and did exploratory analyses of heterogeneity of effect. This trial is registered with ClinicalTrials.gov, number NCT00002511.1005 patients were randomly assigned to a wait-and-see policy (n=503) or postoperative irradiation (n=502) and were followed up for a median of 10·6 years (range 2 months to 16·6 years). Postoperative irradiation significantly improved biochemical progression-free survival compared with the wait-and-see policy (198 [39·4%] of 502 patients in postoperative irradiation group vs 311 [61·8%] of 503 patients in wait-and-see group had biochemical or clinical progression or died; HR 0·49 [95% CI 0·41-0·59]; p0·0001). Late adverse effects (any type of any grade) were more frequent in the postoperative irradiation group than in the wait-and-see group (10 year cumulative incidence 70·8% [66·6-75·0] vs 59·7% [55·3-64·1]; p=0.001).Results at median follow-up of 10·6 years show that conventional postoperative irradiation significantly improves biochemical progression-free survival and local control compared with a wait-and-see policy, supporting results at 5 year follow-up; however, improvements in clinical progression-free survival were not maintained. Exploratory analyses suggest that postoperative irradiation might improve clinical progression-free survival in patients younger than 70 years and in those with positive surgical margins, but could have a detrimental effect in patients aged 70 years or older.Ligue Nationale contre le Cancer (Comité de l'Isère, Grenoble, France) and the European Organisation for Research and Treatment of Cancer (EORTC) Charitable Trust.
Databáze: OpenAIRE
Externí odkaz: